Compare Cintas Corporation (CTAS) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cintas Corporation vs Illumina, Inc. — how do they compare? Cintas Corporation trades at $200.75 (market cap $79.86B), while Illumina, Inc. trades at $266.99 (market cap $39.95B). The key difference: Cintas Corporation is the larger of the two by market cap, and Cintas Corporation pays a 1.03% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cintas Corporation for 124 Days and Illumina, Inc. for 83 Days on average.
| CTAS | ILMN | |
|---|---|---|
Market Cap | $79.86B | $39.95B |
Volume | 1,323,583 | 3,169,503 |
Sector | Industrials | Health |
52-Week High | $216.53 | $293.69 |
52-Week Low | $163.55 | $91.00 |
Typical Hold Time | 124 Days | 83 Days |
Enterprise Value | $82.33B | $41.31B |
Dividend Yield | 1.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cintas (CTAS) trades at $197.19, up 0.63% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q1 2027 results with revenue of $3.01 billion, beating estimates, and raised full-year guidance. Fundamentals show robust revenue growth, expanding margins, and high profitability, though valuation multiples like a P/E of 39.67 are elevated. Analyst sentiment is moderately bullish with a consensus price target of $234.60.
The outlook for CTAS is positive, driven by durable growth, record margins, and strong capital returns. Key opportunities include consistent earnings beats and market leadership, while risks involve high valuation sensitivity and competitive pressures. The stock's upside potential is supported by analyst targets, but investors should monitor execution against guidance.
Illumina (ILMN) trades at $267.76, down 2.11% on the day but remains near its 52-week high. The stock exhibits a bullish technical trend with strong moving average signals, while recent earnings beats and a significant return to profitability in 2025 highlight fundamental improvement. Positive sentiment is fueled by S&P 500 inclusion and analyst upgrades, though high valuation ratios present a risk.
The outlook is cautiously optimistic, driven by sequencing growth and AI initiatives, but investors face risks from elevated valuations, competitive pressures, and potential margin volatility. The consensus price target of $241 suggests near-term downside from current levels despite a majority of analysts maintaining a Buy rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cintas Corporation
In its core uniform and facility services unit (78% of sales), Cintas provides uniform rental programs to businesses across the size spectrum, mostly in North America. The firm is by far the largest provider in the industry. Facilities products generally include the rental and sale of entrance mat, mops, shop towels, hand sanitizers, and restroom supplies. Cintas also runs a first aid and safety services business (11% of sales), a fire protection services business (7% of sales), and a uniform direct sales business (4% of sales).
Read more on CTAS →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
